# FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			or Section So(n) of the investment Company Act of 1940				
1. Name and Addre	ess of Reporting Pers	son <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Mersana Therapeutics, Inc.</u> [ MRSN ]		elationship of Reporting Person(s) to Issuer eck all applicable)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/03/2023		Officer (give title below)	Other (specify below)	
C/O MERSANA THERAPEUTICS, INC. 840 MEMORIAL DRIVE			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X			
(Street)	МА	02139			Form filed by More than Person	One Reporting	
-		(7in)	Rule 10b5-1(c) Transaction Indication	-			
(City)	(State)	(Zip)	1				

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	ount (A) or Price Transa		Reported Transaction(s) (Instr. 3 and 4)			
Common Stock	07/03/2023		Α		6,079(1)	A	\$ <mark>0</mark>	564,011	D		
Common Stock								9,595	I	See Note 2 <sup>(2)</sup>	

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. These shares were granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of fully vested shares of stock rather than cash. The shares were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of \$20,000 for the quarter ended June 30, 2023. The number of shares issued was based on the closing price per share of the Issuer's common stock on June 30, 2023, which was \$3.29.

2. The securities are held directly by the Dave Mott Declaration of Trust dated May 31, 2001, as amended (the "Mott Trust"). The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by the Mott Trust in which the Reporting Person has no pecuniary interest.

/s/ Alejandra Carvajal, Attorney-in-Fact

\*\* Signature of Reporting Person Date

07/06/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5